![Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial - eBioMedicine Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial - eBioMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/60edcec6-04c6-49d6-94a3-f0f5a1f135d5/gr1.jpg)
Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial - eBioMedicine
![ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? | Semantic Scholar ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2aa4c7e96949e3a6786d2b938de5f8c5756a6672/3-Table1-1.png)
ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? | Semantic Scholar
![Frontiers | ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Frontiers | ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?](https://www.frontiersin.org/files/Articles/221704/fnagi-09-00068-HTML/image_m/fnagi-09-00068-t001.jpg)
Frontiers | ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
![Frontiers | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates Frontiers | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates](https://www.frontiersin.org/files/Articles/455919/fneur-10-00835-HTML/image_m/fneur-10-00835-g001.jpg)